Erythropoietin pre-treatment prevents cognitive impairments following status epilepticus in rats

Brain Research

Volumn 1282, Issue , 2009, Pages 57-66

  Jun, Yang ^a   JiangTao, Xu ^a   YuanGui, Huang ^b   YongBin, Song ^a   Jun, Zhen ^a   XiaoJun, Ma ^a   JianChun, Xu ^a   Heng, Xue ^a   XiaoXin, Zhang ^a   XinXiang, Xing ^a  

^a Department of Neurology   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cognitive impairment; Epilepsy; Erythropoietin; Hippocampus; Morris water maze; Status epilepticus

Indexed keywords

DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DNA NUCLEOTIDYLEXOTRANSFERASE; PILOCARPINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; RECOMBINANT ERYTHROPOIETIN; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; EPILEPTIC STATE; HIPPOCAMPUS; IMMUNOFLUORESCENCE TEST; LEARNING; MALE; MAZE TEST; NEUROPATHOLOGY; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; HIPPOCAMPUS; IN SITU NICK-END LABELING; MALE; MAZE LEARNING; MUSCARINIC AGONISTS; NEUROPROTECTIVE AGENTS; PILOCARPINE; RATS; RATS, SPRAGUE-DAWLEY; STATUS EPILEPTICUS;

RATTUS;

EID: 67649641775     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.05.062     Document Type: Article

References (39)

1. Araki T., Simon RP., Taki W., Lan JQ., and Henshall DC. Characterization of neuronal death induced by focally evoked limbic seizures in the C57BL/6 mouse. J. Neurosci. Res. 69 (2002) 614-621
2. Brines ML., Ghezzi P., Keenan S., Agnello D., de Lanerolle NC., Cerami C., Itri LM., and Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10526-10531
3. Chin K., Yu X., Beleslin-Cokic B., Liu C., Shen K., Mohrenweiser H.W., and Noguchi C.T. Production and processing of erythropoietin receptor transcripts in brain. Brain Res. Mol. Brain Res. 81 (2000) 29-42
4. Cory S., and Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2 (2002) 647-656
5. Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin. Cancer Res. 13 (2007) 7254-7263
6. DeGiorgio CM., TRomiyasu U., and Gott PS. Hippocampal pyramidal cell loss in human status epilepticus. Epilepsia 33 (1991) 23-27
7. Duncan JS., Sander JW., Sisodiya SM., and Walker MC. Adult epilepsy. Lancet 367 (2006) 1087-1100
8. Ehrenreich H., Degner D., Meller J., Brines M., Behe M., Hasselblatt M., Woldt H., Falkai P., Knerlich F., Jacob S., von Ahsen N., Maier W., Bruck W., Ruther E., Cerami A., Becker W., and Siren A.L. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol. Psychiatry 9 (2004) 42-54
9. Gorio A., Madaschi L., Di Stefano B., Carelli S., Di Giulio A.M., De Biasi S., Coleman T., Cerami A., and Brines M. Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16379-16384
10. Gross A., Yin X.M., Wang K., Wei M.C., Jockel J., Milliman C., Erdjument-Bromage H., Tempst P., and Korsmeyer SJ. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-X prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274 (1999) 1156-1163
11. Hasselblatt M., Ehrenreich H., and Siren A.L. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J. Neurosurg. Anesthesiol. 18 (2006) 132-138
12. Henshall D.C., Bonislawski D.P., Skradski S.L., Meller R., Lan J.Q., and Simon R.P. Cleavage of Bid may amplify caspase-8-induced neuronal death following focally evoked limbic seizures. Neurobiol. Dis. 8 (2001) 568-580
13. Henshall D.C., and Murphy B.M. Modulators of neuronal cell death in epilepsy. Curr. Opin. Pharmacol. 8 (2007) 1-7
14. Jung, K.H., Chu, K., Lee, S.T., Kim, J., Sinn, D.I., Kim, J.M., Park, D.K., Lee, J.J., Kim, S.U., Kim, M., Lee, S.K., Roh, J.K., 2006. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 23, 237-246.
15. Juul S.E., Yachnis A.T., Rojiani A.M., and Christensen R.D. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr. Dev. Pathol. 2 (1999) 148-158
16. Juul S.E., McPherson R.J., Farrell F.X., Jolliffe L., Ness D.J., and Gleason C.A. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol. Neonate 85 (2004) 138-144
17. Kotloski R., Lynch M., Lauersdorf S., and Sutula T. Repeated brief seizures induce progressive hippocampal neuron loss and memory deficits. Prog. Brain Res. 135 (2002) 95-110
18. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
19. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
20. Manno EM. New management strategies in the treatment of status epilepticus. Mayo. Clin. Proc. 78 (2003) 508-518
21. Marti H.H., Wenger R.H., Rivas L.A., Straumann U., Digicaylioglu M., Henn V., Yonekawa Y., Bauer C., and Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 8 (1996) 666-676
22. Meldrum BS. Implications for neuroprotective treatments. Prog. Brain Res. 135 (2002) 487-495
23. Mikati MA., Abi-Habib RJ., El Sabban ME., Dbaibo GS., Kurdi RM., Kobeissi M., Farhat F., and Asaad W. Hippocampal programmed cell death after status epilepticus: evidence for NMDA-receptor and ceramide-mediated mechanisms. Epilepsia 44 (2003) 282-291
24. Murphy B., Dunleavy M., Shinoda S., Schindler C., Meller R., Bellver-Estelles C., Hatazaki S., Dicker P., Yamamoto A., Koegel I., Chu X., Wang W., Xiong Z., Prehn J., Simon R., and Henshall D.C. Bcl-w protects hippocampus during experimental status epilepticus. Am. J. Pathol. 171 (2007) 1258-1268
25. Nadam J., Navarro F., Sanchez P., Moulin C., Georges B., Laglaine A., Pequignot JM., Morales A., Ryvlin P., and Bezin L. Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus. Neurobiol. Dis. 25 2 (2007) 412-426
26. Paxinos, G., Watson, C., 1997. The Rat Brain in Stereotaxic Coordinates. Academic Press, Inc., San Diego.
27. Polster B.M., and Fiskum G. Mitochondrial mechanisms of neural cell apoptosis. J. Neurochem. 90 (2004) 1281-1289
28. Pouzet B., Zhang W.N., Feldon J., and Rawlins J.N. Hippocampal lesioned rats are able to learn a spatial position using non-spatial strategies. Behav. Brain Res. 133 (2002) 279-291
29. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizures. Electrorencephalogr. Clin. Neurophysiol. 32 (1972) 281-294
30. Robert S., and Barbara G. Effect of 3-aminobenzamine on Bcl-2, Bax and AIF localization in hippocampal neurons altered by ischemia-reperfusion injury. The immunocytochemical study. Acta Neurobiol. Exp. 66 (2006) 15-22
31. Schindler C.K., Shinoda S., Simon R.P., and Henshall D.C. Subcellular distribution of Bcl-2 family proteins and 14-3-3 within the rat hippocampus during seizure-induced neuronal death in the rat. Neurosci. Lett. 356 (2004) 163-166
32. Shinoda S., Schindler C.K., Meller R., So N.K., Araki T., Yamamoto A., Lank J.Q., Taki W., Simon R.P., and Henshall D.C. Bim regulation may determine hippocampal vulnerability after injurious seizures and in temporal lobe epilepsy. J. Clin. Invest. 113 (2004) 1059-1068
33. Siren A.L., Knerlich F., Poser W., Gleiter C.H., Bruck W., and Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. (Berl.) 101 (2001) 271-276
34. Yang J., Huang Y.G., Yu X., Sun H., Li Y.N., and Deng Y.C. Erythropoietin preconditioning suppresses neuronal death following status epilepticus in rats. Acta Neurobiol. Exp. (Wars) 67 2 (2007) 141-148
35. Wang K., Yin X.M., Chao D.T., Milliman C.L., and Korsmeyer S.J. BID: a novel BH3 domain-only death agonist. Genes Dev. 10 (1996) 2859-2869
36. Wang X., Zhu C., Wang X., Gerwien JG., Schrattenholz A., Sandberg M., Leist M., and Blomgren K. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J. Neurochem. 91 (2004) 900-910
37. Wei M.C., Lindsten T., Mootha V.K., Weiler S., Gross A., Ashiya M., Thompson C.B., and Korsmeyer S.J. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14 (2000) 2060-2071
38. Wen X.N., Huang Y.G., and Wang J.C. Erythropoietin preconditioning on hippocampus neuronal apoptosis following status epilepticus induced by Li-pilocarpine in rats through anti-caspase-3 expression. Neurol. India 54 (2006) 58-63
39. White C., Li C., Yang J., Petrenko N.B., Madesh M., Thompson C.B., and Foskett J.K. The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nat. Cell Biol. 7 (2005) 1021-1028